Can a common anesthetic gas help ARDS patients breathe easier?
NCT ID NCT02166853
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether inhaling sevoflurane, a gas usually used for anesthesia, for the first 48 hours could improve oxygen levels and reduce inflammation in 50 adults with moderate to severe ARDS. Participants were randomly assigned to receive either sevoflurane or a standard sedative (midazolam). The main goal was to see if sevoflurane could improve gas exchange in the lungs.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sevoflurane
What this could lead to
If it works, this could point toward a new sedation method that also helps ARDS patients breathe better and reduces lung inflammation.
What could go wrong
This is a small, early-phase study with only 50 participants, so results may not apply broadly. The drug is already used for sedation, but its specific benefit for ARDS is unproven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE RESPIRATORY DISTRESS SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Clermont-Ferrand
Clermont-Ferrand, 63003, France